title: Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
authors.affiliation: Department of Hematology, University Hospital, UMR 1098, Besançon, France.
authors.forename: L
authors.initials: L
authors.lastname: Philippe
authors.affiliation: Department of Oncology, University Hospital, Pointe-a-Pitre, Guadeloupe, France.
authors.forename: P
authors.initials: P
authors.lastname: Helias
authors.affiliation: Department of Clinical methodologies, University Hospital, Besançon, France.
authors.forename: M
authors.initials: M
authors.lastname: Puyraveau
authors.affiliation: Department of Nuclear Medicine, University Hospital, Besançon, France.
authors.forename: H
authors.initials: H
authors.lastname: Boulahdour
authors.affiliation: Department of Hematology, University Hospital, UMR 1098, Besançon, France.
authors.forename: E
authors.initials: E
authors.lastname: Deconinck
authors.affiliation: Department of Hematology, University Hospital, UMR 1098, Besançon, France.
authors.forename: E
authors.initials: E
authors.lastname: Daguindau
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005602:France; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000628:therapy; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D016499:Radioimmunotherapy / Q000379:methods / Q000401:mortality; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D015021:Yttrium Radioisotopes; D003561:Cytarabine; C422802:ibritumomab tiuxetan; D005047:Etoposide; D008558:Melphalan; D002330:Carmustine